Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MARS1 | P56192 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4930153 | 0.86 | KMT2A (0.53) | KMT2AMEN1ALDH1A1CA9FAAH | |
| SCHEMBL4931549 | 0.85 | MARS1 (0.58) | KMT2AMEN1ALDH1A1MARS1 | |
| SCHEMBL5521086 | 0.83 | KMT2A (0.55) | KMT2AMEN1ALDH1A1CA9FAAH | |
| SCHEMBL5266982 | 0.82 | CA9 (0.47) | KMT2ACA9FAAHCHRNA7MGLL | |
| SCHEMBL4923392 | 0.82 | KMT2A (0.53) | KMT2AMEN1ALDH1A1CA9GAA | |
| SCHEMBL4927203 | 0.81 | KMT2A (0.55) | KMT2AMEN1ALDH1A1CA9GAA | |
| SCHEMBL5524647 | 0.81 | KMT2A (0.52) | KMT2AMEN1ALDH1A1CA9FAAH | |
| SCHEMBL18353210 | 0.81 | KMT2A (0.52) | KMT2AMEN1ALDH1A1CA9FAAH | |
| SCHEMBL4932148 | 0.80 | KMT2A (0.54) | KMT2AMEN1ALDH1A1CA9FAAH | |
| SCHEMBL22637367 | 0.80 | KMT2A (0.64) | KMT2AMEN1ALDH1A1GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | KMT2A 1719/4885MEN1 3847/4885ALDH1A1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.